4//SEC Filing
SYNTA PHARMACEUTICALS CORP 4
Accession 0001179110-15-010911
$MDGLCIK 0001157601operating
Filed
Jul 5, 8:00 PM ET
Accepted
Jul 6, 4:31 PM ET
Size
18.4 KB
Accession
0001179110-15-010911
Insider Transaction Report
Form 4
Gollust Keith R
Director
Transactions
- Award
Common Stock
2015-07-01+22,727→ 374,493 total - Award
Common Stock
2015-07-01+13,636→ 388,129 total - Award
Common Stock
2015-07-01+4,545→ 397,219 total - Award
Common Stock
2015-07-01+4,545→ 401,764 total - Award
Director Stock Option (Right to Buy)
2015-07-01+15,000→ 15,000 totalExercise: $2.20Exp: 2025-07-01→ Common Stock (15,000 underlying) - Award
Common Stock
2015-07-01+4,545→ 392,674 total - Award
Director Stock Option (Right to Buy)
2015-07-01+20,000→ 20,000 totalExercise: $2.20Exp: 2025-07-01→ Common Stock (20,000 underlying)
Holdings
- 3,173,383(indirect: By Wyandanch Partners, L.P.)
Common Stock
- 175,000(indirect: By IRA)
Common Stock
Footnotes (8)
- [F1]Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016, provided the Reporting Person continues to serve as a director of the Issuer on such date.
- [F2]Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016, provided the Reporting Person continues to serve as Chairman of the Board of Directors of the Issuer on such date.
- [F3]Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016, provided the Reporting Person continues to serve as Chairman of the Nominating and Governance Committee of the Board of Directors of the Issuer on such date.
- [F4]Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016, provided the Reporting Person continues to serve as a member of the Audit Committee of the Board of Directors of the Issuer on such date.
- [F5]Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016, provided the Reporting Person continues to serve as a member of the Compensation Committee of the Board of Directors of the Issuer on such date.
- [F6]The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F7]The option vests as to 25% of the shares on each of September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016, provided the Reporting Person continues to serve as a director of the Issuer on such date.
- [F8]The option vests as to 25% of the shares on each of September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016, provided the Reporting Person continues to serve as Chairman of the Board of Directors of the Issuer on such date.
Documents
Issuer
SYNTA PHARMACEUTICALS CORP
CIK 0001157601
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001157601
Filing Metadata
- Form type
- 4
- Filed
- Jul 5, 8:00 PM ET
- Accepted
- Jul 6, 4:31 PM ET
- Size
- 18.4 KB